| Literature DB >> 27133816 |
Y Wang1, H-X Wang2, Y-R Lai3, Z-M Sun4, D-P Wu5, M Jiang6, D-H Liu7, K-L Xu8, Q-F Liu9, L Liu10, J-B Wang11, F Gao12, J Ou-Yang13, S-J Gao14, L-P Xu1, X-J Huang1,15.
Abstract
Encouraging results from a small sample of patients with myelodysplastic syndrome (MDS) undergoing haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT) must be extended. Furthermore, an algorithm derived from a comparison of the outcomes of HID and identical-sibling donor (ISD) HSCT must be established. Therefore, the outcomes of 454 MDS patients who underwent HSCT from HIDs (n=226) or ISDs (n=228) between 2003 and 2013 that were reported to the Chinese Bone Marrow Transplantation Registry were analyzed. Among the 3/6 HID (n=136), 4-5/6 HID (n=90) and ISD patient groups, the 4-year adjusted cumulative incidences of non-relapse mortality were 34, 29 and 16%, respectively (overall P=0.004), and of relapse were 6, 7 and 10%, respectively (overall P=0.36). The 4-year adjusted probabilities of overall survival were 58, 63 and 73%, respectively (overall P=0.07), and of relapse-free-survival were 58, 63 and 71%, respectively (overall P=0.14); pairwise comparison showed that the difference was only statistically significant in the 3/6 HID vs ISD pair. The data suggest that ISDs remain the best donor source for MDS patients while HIDs (perhaps 4-5/6 HID in particular) could be a valid alternative when an ISD is not available; human leukocyte antigen disparity had no effect on survival among the HID patients.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27133816 DOI： 10.1038/leu.2016.110
Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528